HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD41 donor lymphocyte infusion

Blood

Volumn 122, Issue 11, 2013, Pages 1963-1973

  Stevanović, Sanja ^a   Van Bergen, Cornelis A M ^a   Van Luxemburg Heijs, Simone A P ^a   Van Der Zouwen, Boris ^a   Jordanova, Ekaterina S ^b   Kruisselbrink, Alwine B ^a   Van De Meent, Marian ^a   Harskamp, Jessica C ^a   Claas, Frans H J ^a   Marijt, Erik W A ^a   Zwaginga, Jaap Jan ^a   Halkes, Constantijn J M ^a   Jedema, Inge ^a   Griffioen, Marieke ^a   Falkenburg, J H Frederik ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; HLA DPB1 ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; TIE 1 RECEPTOR; HLA ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE MYELOID LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL ISOLATION; CHIMERA; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; FEMALE; HEMATOPOIETIC CELL; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SKIN FIBROBLAST; T CELL DEPLETION; T LYMPHOCYTE; TIME TO TREATMENT; UPREGULATION; VIRUS REACTIVATION; ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; BLOOD DONOR; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; METABOLISM; METHODOLOGY; OUTCOME ASSESSMENT; TRANSPLANTATION; VIROLOGY; VIRUS INFECTION;

AGED; BLOOD DONORS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOMEGALOVIRUS; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HLA-DP ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); TRANSPLANTATION, HOMOLOGOUS; UP-REGULATION; VIRUS DISEASES;

EID: 84887340604     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-470872     Document Type: Article

References (50)

1. Barge RM, Starrenburg CW, Falkenburg JHF, Fibbe WE, Marijt EW, Willemze R. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience. Bone Marrow Transplant. 2006;37(12):1129-1134.
2. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78(8):2120-2130.
3. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99(12):4357-4363.
4. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15(2): 433-444.
5. Peggs KS, Thomson K, Hart DP, et al. Doseescalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004; 103(4):1548-1556.
6. Petersdorf EW. Optimal HLA matching in hematopoietic cell transplantation. Curr Opin Immunol. 2008;20(5):588-593.
7. Varney MD, Lester S, McCluskey J, Gao X, Tait BD. Matching for HLA DPA1 and DPB1 alleles in unrelated bone marrow transplantation. Hum Immunol. 1999;60(6):532-538.
8. Aglietta M, Piacibello W, Stacchini A, et al. Expression of HLA class II (DR, DQ) determinants by normal and chronic myeloid leukemia granulocyte/monocyte progenitors. Cancer Res. 1986;46(4 Pt 1):1783-1787.
9. Falkenburg JHF, Jansen J, van der Vaart- Duinkerken N, et al. Polymorphic and monomorphic HLA-DR determinants on human hematopoietic progenitor cells. Blood. 1984;63(5): 1125-1132.
10. Ibisch C, Gallot G, Vivien R, et al. Recognition of leukemic blasts by HLA-DPB1-specific cytotoxic T cell clones: a perspective for adjuvant immunotherapy post-bone marrow transplantation. Bone Marrow Transplant. 1999; 23(11):1153-1159.
11. Orgad S, Yunis EJ, Zaizov R, Ramot B, Altshuler R, Gazit E. Expression of HLA-DR alloantigens on acute lymphoblastic leukemia lymphoblasts. Hum Immunol. 1984;9(2):67-74.
12. Rutten CE, van Luxemburg-Heijs SAP, Griffioen M, et al. HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia. Leukemia. 2008;22(7):1387-1394.
13. Shaw BE, Marsh SG, Mayor NP, Russell NH, Madrigal JA. HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. Blood. 2006;107(3): 1220-1226.
14. Lee SJ, Klein J, Haagenson M, et al. Highresolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13): 4576-4583.
15. Loiseau P, Espérou H, Busson M, et al. DPB1 disparities contribute to severe GVHD and reduced patient survival after unrelated donor bone marrow transplantation. Bone Marrow Transplant. 2002;30(8):497-502.
16. Petersdorf EW, Longton GM, Anasetti C, et al. Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci USA. 1996;93(26): 15358-15363.
17. Petersdorf EW, Longton GM, Anasetti C, et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood. 1995;86(4):1606-1613.
18. Collins T, Korman AJ, Wake CT, et al. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA. 1984;81(15):4917-4921.
19. Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003;17(4): 187-194.
20. Zhang N, Bevan MJ. CD8(1) T cells: foot soldiers of the immune system. Immunity. 2011;35(2): 161-168.
21. Mohty M, Bagattini S, Chabannon C, et al. CD81 T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Exp Hematol. 2004;32(11): 1097-1102.
22. Bevan MJ. Helping the CD8(1) T-cell response. Nat Rev Immunol. 2004;4(8):595-602.
23. Casazza JP, Betts MR, Price DA, et al. Acquisition of direct antiviral effector functions by CMV-specific CD41 T lymphocytes with cellular maturation. J Exp Med. 2006;203(13):2865-2877.
24. Meyer RG, Britten CM, Wehler D, et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reducedintensity transplantation. Blood. 2007;109(1): 374-382.
25. Nimer SD, Giorgi J, Gajewski JL, et al. Selective depletion of CD81 cells for prevention of graftversus- host disease after bone marrow transplantation. A randomized controlled trial. Transplantation. 1994;57(1):82-87.
26. Soiffer RJ, Alyea EP, Hochberg E, et al. Randomized trial of CD81 T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002;8(11):625-632.
27. Van Bergen CAM, Rutten CE, Van Der Meijden ED, et al. High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning. Cancer Res. 2010; 70(22):9073-9083.
28. Rutten CE, van Luxemburg-Heijs SAP, van der Meijden ED, et al. HLA-DPB1 mismatching results in the generation of a full repertoire of HLA-DPB1- specific CD41 T cell responses showing immunogenicity of all HLA-DPB1 alleles. Biol Blood Marrow Transplant. 2010;16(9):1282-1292.
29. Zandvliet ML, van Liempt E, Jedema I, et al. Simultaneous isolation of CD8(1) and CD4(1) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. J Immunother. 2011; 34(3):307-319.
30. Sinzger C, Grefte A, Plachter B, Gouw AS, The TH, Jahn G. Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J Gen Virol. 1995;76(Pt 4):741-750.
31. Beersma MF, Bijlmakers MJ, Ploegh HL. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J Immunol. 1993;151(9):4455-4464.
32. Miller DM, Rahill BM, Boss JM, et al. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J Exp Med. 1998;187(5): 675-683.
33. Waldman WJ, Knight DA, Huang EH. An in vitro model of T cell activation by autologous cytomegalovirus (CMV)-infected human adult endothelial cells: contribution of CMV-enhanced endothelial ICAM-1. J Immunol. 1998;160(7): 3143-3151.
34. Waldman WJ, Knight DA, Adams PW, Orosz CG, Sedmak DD. In vitro induction of endothelial HLA class II antigen expression by cytomegalovirusactivated CD41 T cells. Transplantation. 1993; 56(6):1504-1512.
35. Gaschet J, Lim A, Liem L, et al. Acute graft versus host disease due to T lymphocytes recognizing a single HLA-DPB1∗0501 mismatch. J Clin Invest. 1996;98(1):100-107.
36. Gaschet J, Mahé B, Milpied N, et al. Specificity of T cells invading the skin during acute graft-vs.- host disease after semiallogeneic bone marrow transplantation. J Clin Invest. 1993;91(1):12-20.
37. Rutten CE, van Luxemburg-Heijs SAP, Halkes CJM, et al. Patient HLA-DP-specific CD41 T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graftversus- host disease. Biol Blood Marrow Transplant. 2013;19(1):40-48.
38. Zorn E, Wang KS, Hochberg EP, et al. Infusion of CD41 donor lymphocytes induces the expansion of CD81 donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res. 2002;8(7):2052-2060.
39. Orsini E, Bellucci R, Alyea EP, et al. Expansion of tumor-specific CD81 T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res. 2003;63(10):2561-2568.
40. Collin MP, Hart DN, Jackson GH, et al. The fate of human Langerhans cells in hematopoietic stem cell transplantation. J Exp Med. 2006;203(1): 27-33.
41. Li H, Kaplan DH, Matte-Martone C, et al. Langerhans cells are not required for graft-versushost disease. Blood. 2011;117(2):697-707.
42. Merad M, Hoffmann P, Ranheim E, et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med. 2004;10(5):510-517.
43. van der Zouwen B, Kruisselbrink AB, Jordanova ES, et al. Alloreactive effector T cells require the local formation of a proinflammatory environment to allow crosstalk and high avidity interaction with nonhematopoietic tissues to induce GVHD reactivity. Biol Blood Marrow Transplant. 2012; 18(9):1353-1367.
44. Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versusleukemia effect in acute myeloid leukemia patients. Blood. 2011;118(5):1402-1412.
45. Thomson KJ, Mackinnon S, Peggs KS. CMVspecific cellular therapy for acute myeloid leukemia? Blood. 2012;119(4):1088-1090, author reply 1090-1091.
46. Stevanović S, Griffioen M, Nijmeijer BA, et al. Human allo-reactive CD41 T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia. Leukemia. 2012;26(2):312-322.
47. Brouwer RE, van der Hoorn M, Kluin-Nelemans HC, van Zelderen-Bhola S, Willemze R, Falkenburg JH. The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses. Hum Immunol. 2000;61(6):565-574.
48. Jedema I, Meij P, Steeneveld E, et al. Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFNgamma secretion assay. Clin Cancer Res. 2007; 13(2 Pt 1):636-643.
49. Smit WM, Rijnbeek M, van Bergen CAM, et al. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum Immunol. 1997;53(2): 216-223.
50. Hoogendoorn M, Wolbers JO, Smit WM, et al. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy. Leukemia. 2004;18(7): 1278-1287.